Innate Pharma hires director of clinical development
Dr Benzohra brings Innate Pharma a wealth of experience and know-how in carrying out clinical trials in oncology. He will be in charge of selecting indications for clinical development and designing and monitoring clinical trials as well as managing relations with investigators. This work will be carried out in close collaboration with Innate Pharma's development team, responsible for pre-clinical pharmaco-toxicology. Dr Benzohra will also be part of Innate Pharma's management team defining company strategy and evaluating opportunities to expand its product portfolio. Before joining Innate Pharma, Dr Benzohra was Head of the Oncology and Gynecology Group at Pharmacia SAS from 2001. Previously he was International Medical Project Leader at Pierre Fabre Oncology for two years. He began his career with Roche where he was Project Leader in oncology-hematology from 1994 to 1999. Dr Benzohra qualified as a Doctor in Medicine at the Institute of Medical Sciences in Oran, Algeria, and acquired his certificate of advanced studies in clinical oncology at the Saint-Louis-Lariboisière University in Paris, where he also received training in clinical trials. He is the author of several international publications, dealing mainly with the problems of experimental therapeutics in the field of oncology. "The recruitment of Aziz Benzohra is an important step in Innate Pharma's company strategy," said Hervé Brailly, CEO of Innate Pharma. "It demonstrates that our process of developing new anti-tumoral medicines is moving forward fast. His arrival dovetails in precisely with the roadmap we set ourselves a year ago at our last fund raising which was intended to move us forward in the clinical development of our lead candidates. We are delighted to have him in our team.",About Innate Pharma:,Innate Pharma S.A.S. 'The Innate Immunity Company', is a French biotechnology company developing immuno-modulating medications and cellular therapies based on the novel concept of 'innate immunity' - stimulation of non-conventional lymphocytes. The main field of research is cancerology, with the first clinical trials begun in 2002. The company was founded in 1999 by a group of four European scientists and two managers from the biotech industry. Companies investing in Innate are Sofinnova Partners, Auriga, GIMV, INSERM Transfert, Alta Partners, Axa Private Equity, Gilde Biotech and Nutrition, Pechel Industries and Innoveris.,
Countries
France